{"name":"WPD Pharmaceuticals","slug":"wpd","ticker":"WPDPF","exchange":"OTC","domain":"wpdpharmaceuticals.com","description":"WPD Pharmaceuticals is a biotechnology company focused on CNS oncology. The company is developing several drugs, including WP1732, a potential treatment for glioblastoma. WPD Pharmaceuticals is a relatively small player in the CNS oncology market, but its pipeline holds promise for future growth.","hq":"Warsaw, Poland","founded":0,"employees":"","ceo":"Mariusz Olejniczak","sector":"Biotechnology / CNS Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$8M","metrics":{"revenue":150000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"WP1732 patent cliff ($0.0B at risk)","drug":"WP1732","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"WPD Pharmaceuticals Reports Q4 2023 Financial Results","summary":"WPD Pharmaceuticals reported its Q4 2023 financial results, with revenue of $0.2 million and a net loss of $2.5 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"WPD Pharmaceuticals Enters into Licensing Agreement with University of British Columbia","summary":"WPD Pharmaceuticals entered into a licensing agreement with the University of British Columbia to develop and commercialize WP1732, a potential treatment for glioblastoma.","drugName":"","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"WP1732","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Celldex Therapeutics","Puma Biotechnology","Clovis Oncology"],"therapeuticFocus":["CNS oncology"],"financials":null,"yahoo":null}